Where’s The Tipping Point? Pacira Pharmaceuticals, Inc. (PCRX), Alteryx, Inc. (AYX)

7 analysts out of 15 Wall Street brokerage firms rate Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) as a Buy, while 2 see it as a Sell. The rest 6 …

7 analysts out of 15 Wall Street brokerage firms rate Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) as a Buy, while 2 see it as a Sell. The rest 6 describe it as a Hold. PCRX stock traded higher to an intra-day high of $38.17. At one point in session, its potential discontinued and the price was down to lows at $37.27. Analysts have set PCRX’s consensus price at $52, effectively giving it a 38.33% projection on returns. Should the projected estimates be met, then the stock will likely hit its highest price at $85 (up 126.12% from current price levels). PCRX has a -0.2% ROE, lower than the 15.46% average for the industry. The average ROE for the sector is 15.25%.

It is expected that in Mar 2019 quarter PCRX will have an EPS of $0.05, suggesting a 127.78% growth. For Jun 2019 is projected at $0.11. It means that there could be a 57.14% growth in the quarter. Yearly earnings are expected to rise by 141.38% to about $0.7. As for the coming year, growth will be about -28.57%, lifting earnings to $0.5. RSI after the last trading period was 43.61. PCRX recorded a change of -3.81% over the past week and returned -18.69% over the last three months while the PCRX stock’s monthly performance revealed a shift in price of 0.03%. The year to date (YTD) performance stands at -12.62%, and the bi-yearly performance specified an activity trend of -16.37% while the shares have moved 17.84% for the past 12 months.

Pacira Pharmaceuticals, Inc. (PCRX) currently trades at $37.59, which is lower by -0.5% its previous price. It has a total of 41.51 million outstanding shares, with an ATR of around 1.84. The company’s stock volume dropped to 0.49 million, worse than 635.21 thousands that represents its 50-day average. A 5-day decrease of about -3.81% in its price means PCRX is now -12.62% lower on year-to-date. The shares have surrendered $43154.41 since its $55.00 52-week high price recorded on 2nd of November 2018. Overall, it has seen a growth rate of 17.84 over the last 12 months. The current price per share is $10.64 above the 52 week low of $26.95 set on 2nd of April 2018.

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX)’s EPS was $0.47 as reported for the December quarter. In comparison, the same quarter a year ago had an EPS of $0.38. That means that its growth in general now stands at 24%. Therefore, a prediction of $0.28 given by the analysts brought a positive surprise of 68%. PCRX Dec 19 quarter revenue was $95.11 million, compared to $79.08 million recorded in same quarter last year, giving it a 20% growth rate. The company’s $16.03 million revenue growth that quarter surprised Wall Street and investors will need to consider this as they assess the stock.

Alteryx, Inc. (NYSE:AYX) shares appreciated 1.18% over the last trading period, taking overall 5-day performance up to 13.49%. AYX’s price now at $76.06 is greater than the 50-day average of $69.59. Getting the trading period increased to 200 days, the stock price was seen at $54.76 on average. The general public currently hold control of a total of 37.7 million shares, which is the number publicly available for trading. The total of shares that it has issued to investors is 61.6 million. The company’s management holds a total of 0.5%, while institutional investors hold about 0% of the remaining shares. AYX share price finished last trade 5.33% above its 20 day simple moving average and its upbeat gap from 200 day simple moving average is 39.46%, while closing the session with 9.82% distance from 50 day simple moving average.

Alteryx, Inc. (AYX) shares were last observed trading -4.89% down since February 28, 2019 when the peak of $79.97 was hit. Last month’s price growth of 8.83% puts AYX performance for the year now at 27.9%. Consequently, the shares price is trending higher by 149.79%, a 52-week worst price since Apr. 27, 2018. However, it is regaining value with 26.77% in the last 6 months. From a technical perspective, it appears more likely that the stock will experience a Bull Run market as a result of the strong support seen recently between $73.18 and $74.62. The immediate resistance area is now $77.11 Williams’s %R (14) for AYX moved to 25.31 while the stochastic %K points at 64.01.

AYX’s beta is 0; meaning investors could reap lower returns, although it also poses lower risks. The company allocated $0.33 per share from its yearly profit to its outstanding shares. Its last reported revenue is $60.51 million, which was 57% versus $38.59 million in the corresponding quarter last year. The EPS for Dec 19 quarter came in at $-0.01 compared to $0.02 in the year-ago quarter and had represented -150% year-over-year earnings per share growth. AYX’s ROA is 5.8%, lower than the 9.29% industry average. Although a more robust percentage would be better, consideration is given to how well peers within the industry performed. Companies within the sector had an ROA of 10.48%.

Estimated quarterly earnings for Alteryx, Inc. (NYSE:AYX) are around $-0.16 per share in three months through March with $-0.13 also the estimate for June quarter of the fiscal year. It means the growth is estimated at -128.57% and 13.33%, respectively. Analysts estimate full-year growth to be 130%, the target being $0.06 a share. The upcoming year will see an increase in growth by percentage to 300%, more likely to see it hit the $0.24 per share. The firm’s current profit margin over the past 12 months is 11.1%. AYX ranks lower in comparison to an average of 11.72% for industry peers; while the average for the sector is 12.27%.

Related Posts:

  • No Related Posts

Biogen Inc (NASDAQ:BIIB) Shares Sold by Castleark Management LLC

AQR Capital Management LLC increased its position in Biogen by 6.5% during the third quarter. AQR Capital Management LLC now owns 3,024,037 …

Biogen logoCastleark Management LLC lessened its position in Biogen Inc (NASDAQ:BIIB) by 45.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,759 shares of the biotechnology company’s stock after selling 17,306 shares during the period. Castleark Management LLC’s holdings in Biogen were worth $6,247,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. BlackRock Inc. increased its position in Biogen by 0.4% during the fourth quarter. BlackRock Inc. now owns 16,568,963 shares of the biotechnology company’s stock worth $4,985,931,000 after purchasing an additional 70,603 shares during the last quarter. Oregon Public Employees Retirement Fund increased its position in Biogen by 27,620.0% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 14,309,047 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 14,257,427 shares during the last quarter. AQR Capital Management LLC increased its position in Biogen by 6.5% during the third quarter. AQR Capital Management LLC now owns 3,024,037 shares of the biotechnology company’s stock worth $1,068,422,000 after purchasing an additional 183,542 shares during the last quarter. Capital World Investors increased its position in Biogen by 503.2% during the third quarter. Capital World Investors now owns 2,473,708 shares of the biotechnology company’s stock worth $873,986,000 after purchasing an additional 2,063,598 shares during the last quarter. Finally, Jackson Square Partners LLC grew its stake in Biogen by 5.7% during the third quarter. Jackson Square Partners LLC now owns 2,241,778 shares of the biotechnology company’s stock worth $792,042,000 after buying an additional 121,072 shares during the period. 88.94% of the stock is owned by institutional investors and hedge funds.

BIIB has been the subject of several research reports. BMO Capital Markets assumed coverage on shares of Biogen in a research note on Friday, February 22nd. They set a “market perform” rating and a $322.00 price objective for the company. Mizuho set a $427.00 target price on shares of Biogen and gave the company a “buy” rating in a research note on Tuesday, January 29th. Oppenheimer decreased their target price on shares of Biogen from $380.00 to $372.00 and set an “outperform” rating for the company in a research note on Tuesday, December 18th. Royal Bank of Canada cut their price target on shares of Biogen to $338.00 and set a “sector perform” rating on the stock in a report on Monday, November 26th. Finally, ValuEngine cut shares of Biogen from a “hold” rating to a “sell” rating in a report on Wednesday, December 19th. Ten analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $370.28.

Shares of BIIB stock traded up $6.55 during trading hours on Wednesday, reaching $319.27. The stock had a trading volume of 17,327 shares, compared to its average volume of 1,233,484. The company has a quick ratio of 2.04, a current ratio of 2.32 and a debt-to-equity ratio of 0.46. Biogen Inc has a twelve month low of $249.17 and a twelve month high of $388.67. The stock has a market cap of $61.45 billion, a PE ratio of 12.17, a price-to-earnings-growth ratio of 1.15 and a beta of 1.13.

Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Tuesday, January 29th. The biotechnology company reported $6.99 earnings per share for the quarter, topping the Zacks’ consensus estimate of $6.72 by $0.27. Biogen had a net margin of 32.94% and a return on equity of 40.53%. The business had revenue of $3.53 billion for the quarter, compared to analysts’ expectations of $3.39 billion. During the same quarter last year, the company earned $5.26 EPS. The company’s revenue for the quarter was up 6.6% compared to the same quarter last year. Equities analysts forecast that Biogen Inc will post 28.68 EPS for the current fiscal year.

In related news, Director Alexander J. Denner purchased 7,000 shares of Biogen stock in a transaction dated Friday, February 1st. The stock was acquired at an average cost of $328.45 per share, with a total value of $2,299,150.00. Following the completion of the transaction, the director now directly owns 10,909 shares of the company’s stock, valued at $3,583,061.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Alexander J. Denner purchased 30,000 shares of Biogen stock in a transaction dated Wednesday, January 30th. The stock was bought at an average cost of $324.86 per share, with a total value of $9,745,800.00. Following the completion of the transaction, the director now directly owns 10,909 shares of the company’s stock, valued at $3,543,897.74. The disclosure for this purchase can be found here. Company insiders own 0.29% of the company’s stock.

WARNING: “Biogen Inc (NASDAQ:BIIB) Shares Sold by Castleark Management LLC” was first reported by Fairfield Current and is the property of of Fairfield Current. If you are reading this article on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this article can be viewed at https://www.fairfieldcurrent.com/news/2019/03/13/biogen-inc-biib-shares-sold-by-castleark-management-llc.html.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis.

Recommended Story: Net Margin

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Biogen and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

BlackRock Inc. Grows Position in New Residential Investment Corp (NRZ)

BlackRock Inc. increased its position in shares of New Residential Investment Corp (NYSE:NRZ) by 6.8% during the fourth quarter, according to its …

New Residential Investment logoBlackRock Inc. increased its position in shares of New Residential Investment Corp (NYSE:NRZ) by 6.8% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 22,189,175 shares of the real estate investment trust’s stock after buying an additional 1,406,824 shares during the quarter. BlackRock Inc. owned about 6.52% of New Residential Investment worth $315,310,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in NRZ. Russell Investments Group Ltd. raised its stake in shares of New Residential Investment by 22.3% during the third quarter. Russell Investments Group Ltd. now owns 68,246 shares of the real estate investment trust’s stock valued at $1,216,000 after acquiring an additional 12,433 shares during the last quarter. State Board of Administration of Florida Retirement System increased its position in shares of New Residential Investment by 14.8% during the third quarter. State Board of Administration of Florida Retirement System now owns 342,936 shares of the real estate investment trust’s stock worth $6,111,000 after buying an additional 44,176 shares during the period. Victory Capital Management Inc. increased its position in shares of New Residential Investment by 50.1% during the third quarter. Victory Capital Management Inc. now owns 10,947 shares of the real estate investment trust’s stock worth $195,000 after buying an additional 3,655 shares during the period. Stratos Wealth Partners LTD. increased its position in shares of New Residential Investment by 27.2% during the third quarter. Stratos Wealth Partners LTD. now owns 18,723 shares of the real estate investment trust’s stock worth $334,000 after buying an additional 4,001 shares during the period. Finally, Wells Fargo & Company MN increased its position in shares of New Residential Investment by 96.3% during the third quarter. Wells Fargo & Company MN now owns 2,878,288 shares of the real estate investment trust’s stock worth $51,292,000 after buying an additional 1,412,178 shares during the period. Hedge funds and other institutional investors own 54.30% of the company’s stock.

In other news, CEO Michael Nierenberg acquired 60,000 shares of the firm’s stock in a transaction dated Friday, February 22nd. The stock was bought at an average cost of $16.50 per share, for a total transaction of $990,000.00. Following the completion of the transaction, the chief executive officer now directly owns 995,352 shares in the company, valued at approximately $16,423,308. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.93% of the company’s stock.

NRZ opened at $16.66 on Wednesday. New Residential Investment Corp has a twelve month low of $13.86 and a twelve month high of $18.75. The firm has a market cap of $6.83 billion, a PE ratio of 7.00, a PEG ratio of 7.14 and a beta of 1.10.

New Residential Investment (NYSE:NRZ) last posted its quarterly earnings data on Tuesday, February 12th. The real estate investment trust reported $0.58 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.55 by $0.03. New Residential Investment had a net margin of 57.58% and a return on equity of 13.88%. The company had revenue of $266.00 million during the quarter, compared to analysts’ expectations of $210.42 million. During the same period in the prior year, the company posted $0.61 earnings per share. Research analysts anticipate that New Residential Investment Corp will post 2.32 EPS for the current year.

NRZ has been the subject of several recent analyst reports. Zacks Investment Research cut shares of New Residential Investment from a “buy” rating to a “hold” rating in a research report on Tuesday, January 15th. Credit Suisse Group reiterated a “buy” rating and set a $18.00 price objective on shares of New Residential Investment in a research report on Friday, January 4th. Two investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $19.57.

ILLEGAL ACTIVITY NOTICE: “BlackRock Inc. Grows Position in New Residential Investment Corp (NRZ)” was originally posted by Fairfield Current and is the sole property of of Fairfield Current. If you are accessing this story on another website, it was stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this story can be read at https://www.fairfieldcurrent.com/news/2019/03/13/blackrock-inc-grows-position-in-new-residential-investment-corp-nrz.html.

About New Residential Investment

New Residential Investment Corp., a real estate investment trust, focuses on investing in and managing residential mortgage related assets in the United States. It operates through Servicing Related Assets, Residential Securities and Loans, and Other Investments segments. The company invests in excess mortgage servicing rights (MSRs) on residential mortgage loans; and in servicer advances, including the basic fee component of the related MSRs.

Featured Story: Earnings Reports

Want to see what other hedge funds are holding NRZ?Visit HoldingsChannel.com to get the latest 13F filings and insider trades for New Residential Investment Corp (NYSE:NRZ).

Institutional Ownership by Quarter for New Residential Investment (NYSE:NRZ)

Receive News & Ratings for New Residential Investment Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for New Residential Investment and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Shedding Some Light on the Technicals For Finisar Corporation (NasdaqGS:FNSR), Genesee …

At the time of writing, Finisar Corporation (NasdaqGS:FNSR) has a Piotroski F-Score of 4. The F-Score may help discover companies with …

At the time of writing, Finisar Corporation (NasdaqGS:FNSR) has a Piotroski F-Score of 4. The F-Score may help discover companies with strengthening balance sheets. The score may also be used to spot the weak performers. Joseph Piotroski developed the F-Score which employs nine different variables based on the company financial statement. A single point is assigned to each test that a stock passes. Typically, a stock scoring an 8 or 9 would be seen as strong. On the other end, a stock with a score from 0-2 would be viewed as weak.

As we move closer towards the end of the year, investors might be looking over the portfolio and trying to see what has been working and what hasn’t been. Investors may be studying the most recent earnings reports of stocks they own in order to make sure that everything is still in order. Active investors might be double checking the portfolio to make sure that it is properly diversified. There might be a few adjustments that need to be made in order to keep the holdings balanced. Of course, nobody can say for sure which way the momentum will shift over the next couple of quarters, but being prepared for any situation is generally considered to be a good idea.

Current Ratio

The Current Ratio of Finisar Corporation (NasdaqGS:FNSR) is 6.79. The Current Ratio is used by investors to determine whether a company can pay short term and long term debts. The current ratio looks at all the liquid and non-liquid assets compared to the company’s total current liabilities. A high current ratio indicates that the company might have trouble managing their working capital. A low current ratio (when the current liabilities are higher than the current assets) indicates that the company may have trouble paying their short term obligations.

The Return on Invested Capital (aka ROIC) for Finisar Corporation (NasdaqGS:FNSR) is -0.033862. The Return on Invested Capital is a ratio that determines whether a company is profitable or not. It tells investors how well a company is turning their capital into profits. The ROIC is calculated by dividing the net operating profit (or EBIT) by the employed capital. The employed capital is calculated by subrating current liabilities from total assets. Similarly, the Return on Invested Capital Quality ratio is a tool in evaluating the quality of a company’s ROIC over the course of five years. The ROIC Quality of Finisar Corporation (NasdaqGS:FNSR) is 5.856383. This is calculated by dividing the five year average ROIC by the Standard Deviation of the 5 year ROIC. The ROIC 5 year average is calculated using the five year average EBIT, five year average (net working capital and net fixed assets). The ROIC 5 year average of Finisar Corporation (NasdaqGS:FNSR) is 0.101483.

The Gross Margin Score is calculated by looking at the Gross Margin and the overall stability of the company over the course of 8 years. The score is a number between one and one hundred (1 being best and 100 being the worst). The Gross Margin Score of Finisar Corporation (NasdaqGS:FNSR) is 37.00000. The more stable the company, the lower the score. If a company is less stable over the course of time, they will have a higher score.

MF Rank

The MF Rank (aka the Magic Formula) is a formula that pinpoints a valuable company trading at a good price. The formula is calculated by looking at companies that have a high earnings yield as well as a high return on invested capital. The MF Rank of Finisar Corporation (NasdaqGS:FNSR) is 12310. A company with a low rank is considered a good company to invest in. The Magic Formula was introduced in a book written by Joel Greenblatt, entitled, “The Little Book that Beats the Market”.

The Q.i. Value of Finisar Corporation (NasdaqGS:FNSR) is 62.00000. The Q.i. Value is a helpful tool in determining if a company is undervalued or not. The Q.i. Value is calculated using the following ratios: EBITDA Yield, Earnings Yield, FCF Yield, and Liquidity. The lower the Q.i. value, the more undervalued the company is thought to be.

Turning to Free Cash Flow Growth (FCF Growth), this is the free cash flow of the current year minus the free cash flow from the previous year, divided by last year’s free cash flow. The FCF Growth of Finisar Corporation (NasdaqGS:FNSR) is -1.568437. Free cash flow (FCF) is the cash produced by the company minus capital expenditure. This cash is what a company uses to meet its financial obligations, such as making payments on debt or to pay out dividends. The Free Cash Flow Score (FCF Score) is a helpful tool in calculating the free cash flow growth with free cash flow stability – this gives investors the overall quality of the free cash flow.

Value Composite

The Value Composite One (VC1) is a method that investors use to determine a company’s value. The VC1 of Finisar Corporation (NasdaqGS:FNSR) is 55. A company with a value of 0 is thought to be an undervalued company, while a company with a value of 100 is considered an overvalued company.

The VC1 is calculated using the price to book value, price to sales, EBITDA to EV, price to cash flow, and price to earnings. Similarly, the Value Composite Two (VC2) is calculated with the same ratios, but adds the Shareholder Yield. The Value Composite Two of Finisar Corporation (NasdaqGS:FNSR) is 62.

Volatility

Stock volatility is a percentage that indicates whether a stock is a desirable purchase. Investors look at the Volatility 12m to determine if a company has a low volatility percentage or not over the course of a year. The Volatility 12m of Finisar Corporation (NasdaqGS:FNSR) is 41.450100. This is calculated by taking weekly log normal returns and standard deviation of the share price over one year annualized.

The lower the number, a company is thought to have low volatility. The Volatility 3m is a similar percentage determined by the daily log normal returns and standard deviation of the share price over 3 months. The Volatility 3m of Finisar Corporation (NasdaqGS:FNSR) is 23.927400. The Volatility 6m is the same, except measured over the course of six months. The Volatility 6m is 38.965600.

ERP5 Rank

The ERP5 Rank is an investment tool that analysts use to discover undervalued companies. The ERP5 looks at the Price to Book ratio, Earnings Yield, ROIC and 5 year average ROIC. The ERP5 of Finisar Corporation (NasdaqGS:FNSR) is 11603. The lower the ERP5 rank, the more undervalued a company is thought to be.

As we move closer towards the end of the year, investors might be looking over the portfolio and trying to see what has been working and what hasn’t been. Investors may be studying the most recent earnings reports of stocks they own in order to make sure that everything is still in order. Active investors might be double checking the portfolio to make sure that it is properly diversified. There might be a few adjustments that need to be made in order to keep the holdings balanced. Of course, nobody can say for sure which way the momentum will shift over the next couple of quarters, but being prepared for any situation is generally considered to be a good idea.

Genesee & Wyoming Inc. (NYSE:GWR) has a Piotroski F-Score of 6 at the time of writing. The F-Score may help discover companies with strengthening balance sheets. The score may also be used to spot the weak performers.

Joseph Piotroski developed the F-Score which employs nine different variables based on the company financial statement. A single point is assigned to each test that a stock passes. Typically, a stock scoring an 8 or 9 would be seen as strong. On the other end, a stock with a score from 0-2 would be viewed as weak.

Investors might be looking to rebuild the portfolio as we move into the second half of the year. New investors can be tempted to try to maximize returns by owning one specific sector or be exposed to a fairly large single investment. By diversifying the portfolio, investors might be able to protect themselves from a sudden move against the position. Finding the correct portfolio balance is how many investors choose to approach the markets. This may take some time to master, and there may be some bumps along the way. Investors managing their own money may want to make sure that they know exactly what stocks are in the portfolio at all times. Keeping tabs on portfolio performance can also be a good way to make sure that it is weighted properly.

Return on Invested Capital (ROIC), ROIC Quality, ROIC 5 Year Average

The Return on Invested Capital (aka ROIC) for Genesee & Wyoming Inc. (NYSE:GWR) is 0.087640. The Return on Invested Capital is a ratio that determines whether a company is profitable or not. It tells investors how well a company is turning their capital into profits. The ROIC is calculated by dividing the net operating profit (or EBIT) by the employed capital. The employed capital is calculated by subrating current liabilities from total assets. Similarly, the Return on Invested Capital Quality ratio is a tool in evaluating the quality of a company’s ROIC over the course of five years. The ROIC Quality of Genesee & Wyoming Inc. (NYSE:GWR) is 4.530250. This is calculated by dividing the five year average ROIC by the Standard Deviation of the 5 year ROIC. The ROIC 5 year average is calculated using the five year average EBIT, five year average (net working capital and net fixed assets). The ROIC 5 year average of Genesee & Wyoming Inc. (NYSE:GWR) is 0.093614.

Leverage Ratio

The Leverage Ratio of Genesee & Wyoming Inc. (NYSE:GWR) is 0.310374. Leverage ratio is the total debt of a company divided by total assets of the current and past year divided by two. Companies take on debt to finance their day to day operations. The leverage ratio can measure how much of a company’s capital comes from debt. With this ratio, investors can better estimate how well a company will be able to pay their long and short term financial obligations.

Return on Assets

There are many different tools to determine whether a company is profitable or not. One of the most popular ratios is the “Return on Assets” (aka ROA). This score indicates how profitable a company is relative to its total assets. The Return on Assets for Genesee & Wyoming Inc. (NYSE:GWR) is 0.030420. This number is calculated by dividing net income after tax by the company’s total assets. A company that manages their assets well will have a higher return, while a company that manages their assets poorly will have a lower return.

Turning to Free Cash Flow Growth (FCF Growth), this is the free cash flow of the current year minus the free cash flow from the previous year, divided by last year’s free cash flow. The FCF Growth of Genesee & Wyoming Inc. (NYSE:GWR) is 0.511213. Free cash flow (FCF) is the cash produced by the company minus capital expenditure. This cash is what a company uses to meet its financial obligations, such as making payments on debt or to pay out dividends.

The Free Cash Flow Score (FCF Score) is a helpful tool in calculating the free cash flow growth with free cash flow stability – this gives investors the overall quality of the free cash flow.

Stock volatility is a percentage that indicates whether a stock is a desirable purchase. Investors look at the Volatility 12m to determine if a company has a low volatility percentage or not over the course of a year. The Volatility 12m of Genesee & Wyoming Inc. (NYSE:GWR) is 22.227500. This is calculated by taking weekly log normal returns and standard deviation of the share price over one year annualized.

The lower the number, a company is thought to have low volatility. The Volatility 3m is a similar percentage determined by the daily log normal returns and standard deviation of the share price over 3 months. The Volatility 3m of Genesee & Wyoming Inc. (NYSE:GWR) is 32.852900. The Volatility 6m is the same, except measured over the course of six months. The Volatility 6m is 31.567400.

ERP5 Rank

The ERP5 Rank is an investment tool that analysts use to discover undervalued companies. The ERP5 looks at the Price to Book ratio, Earnings Yield, ROIC and 5 year average ROIC. The ERP5 of Genesee & Wyoming Inc. (NYSE:GWR) is 7093. The lower the ERP5 rank, the more undervalued a company is thought to be.

MF Rank

The MF Rank (aka the Magic Formula) is a formula that pinpoints a valuable company trading at a good price. The formula is calculated by looking at companies that have a high earnings yield as well as a high return on invested capital. The MF Rank of Genesee & Wyoming Inc. (NYSE:GWR) is 7370. A company with a low rank is considered a good company to invest in. The Magic Formula was introduced in a book written by Joel Greenblatt, entitled, “The Little Book that Beats the Market”.

Investing in the stock market can sometimes be a wild ride. Without the proper planning and research, investors may quickly find themselves on the outside looking in. Doing the research and studying the market can be helpful, but creating a trading or investing plan may be the most important part of the process. When the back testing and practice is completed, the real challenge awaits. The practice and preparation can be very helpful for understanding the market, but when real money gets put on the line, it can be a whole different ballgame. The more successful traders and investors are the ones who are able to stay focused and disciplined even throughout turbulent market situations.

The Q.i. Value of Genesee & Wyoming Inc. (NYSE:GWR) is 32.00000. The Q.i. Value is a helpful tool in determining if a company is undervalued or not. The Q.i. Value is calculated using the following ratios: EBITDA Yield, Earnings Yield, FCF Yield, and Liquidity. The lower the Q.i. value, the more undervalued the company is thought to be.

The Value Composite One (VC1) is a method that investors use to determine a company’s value. The VC1 of Genesee & Wyoming Inc. (NYSE:GWR) is 32. A company with a value of 0 is thought to be an undervalued company, while a company with a value of 100 is considered an overvalued company. The VC1 is calculated using the price to book value, price to sales, EBITDA to EV, price to cash flow, and price to earnings. Similarly, the Value Composite Two (VC2) is calculated with the same ratios, but adds the Shareholder Yield. The Value Composite Two of Genesee & Wyoming Inc. (NYSE:GWR) is 24.

With the stock market continuing to move higher, investors may be searching for stocks that are still fairly undervalued. This may involve doing a little bit more homework than usual. Spotting those names that have been cast aside and not garnering much recent attention might be a good place to start. Putting in a few extra hours of stock research may provide some good options for buying on the next big dip. Of course, nobody can say for sure how long the markets will continue to climb. Being ready for a pullback can help if investors already have some names in mind that they are looking to scoop up when they fall to a certain level. Tracking the technicals and staying up on the fundamentals should help investors hone in on the next wave of stocks to add to the portfolio.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Laredo Petroleum, Inc. (LPI) – Hot stock Alert

Insiders own 1.40% of Laredo Petroleum, Inc. (LPI) shares. … Laredo Petroleum, Inc. (LPI) recently closed with fall of -12.19% to its 20-Day Simple …

LPI Stock of Tuesday with Moved of 4.41%

Laredo Petroleum, Inc. (LPI) stock price traded with surging change along with the volume 6.4 million shares in 12 March trading session. Shares are trading price at $3.08 with move of 4.41%. The company’s 3-months average volume stands at 4.8 million. When we divide the last trade volume by the 3-month average volume, we found out a relative volume of 1.28. Recent trade price levels places LPI’s stock about -72.44% away from the 52-week high and closed 10.00% away from the 52-week low. The total dollar value of all 246.55 million outstanding shares is 0.76 billion. EPS in next five year years is expected to touch 10.49% while EPS growth in past 5 year was 9.90% along with sales growth of 10.70% in the last five years. EPS growth in next year is estimated to reach 58.17% while EPS growth estimate for this year is set at -39.10%.

The net percent change held by Institutional Investors has seen a change of -3.83% in last three month period. Insiders own 1.40% of Laredo Petroleum, Inc. (LPI) shares. During last six month record, the net percent change kept by insiders has observed a change of -91.45%. The stock volatility for week was 6.54% while for month was 6.30%.

Return on Assets (ROA) ratio indicates how profitable a company is relative to its total assets. The ROA is 14.40%. A company that manages their assets well will have a high return, while if manages their assets poorly will have a low return.

Common shareholders want to know how profitable their capital is in the businesses they invest it in. The company gives a ROE of 31.70%. The higher the ROE, the better the company is at generating profits.

ROI is 16.00%. A positive result means that returns exceed costs. Analysts therefore consider the investment a net gain. The opposite kind of result, a negative means that costs outweigh returns. Analysts therefore view the investment as a net loss.

Laredo Petroleum, Inc. (LPI) recently closed with fall of -12.19% to its 20-Day Simple Moving Average. This short time frame picture represents a downward movement of current price over average price of last 20 days. Now moving toward intermediate time frame, 50-day Moving average is more useful at showing position trading trends lasting 50 days. Shares of LPI moved downward with change of -16.52% to its 50-day Moving average. This falling movement shows negative prices direction over last 50 days.

Finally observing long term time frame, 200-day simple moving average is more helpful at telling general investing trends lasting 200 days. Longer moving average timeframes are less sensitive to price fluctuations than shorter term timeframes and will generate far few signals. This will reduce the number of “whipsaws”, which is good, but will also generate signals later than when using shorter term averages. LPI stock price revealed pessimistic move of -52.40% comparing average price of last 200 days. This comparison showed down direction of price behind its 200-SMA.

ATR value of company was 0.21. Average True Range (ATR) is an indicator based on trading ranges smoothed by an N-period exponential moving average percentage of the true range values. ATR can display volatility of stocks, ETFs and indexes. The principal of ATR is very similar to other volatility indicators: A high ATR value signals a possible trend change. A low ATR value correlates with a weaker trend movement.

Kelly Snell is passionate about Basic Materials and finance news with over 5 years in the industry starting as a writer working his way up into senior positions. She is the driving force behind Top desert safari with a vision to broaden the company’s readership throughout 2016. Kelly is an editor and reporter of news about Basic Materials Sector Companies.

Related Posts:

  • No Related Posts